User profiles for Lauren Pischel
 | Lauren PischelYale University Verified email at Yale.edu Cited by 627 |
Tocilizumab treatment for cytokine release syndrome in hospitalized patients with coronavirus disease 2019: survival and clinical outcomes
… Altice MD b f , Yu Shyr PhD g , Alan Koff MBBS b , Lauren Pischel MD b , George Goshua
MD c , Marwan M. Azar MD b , Dayna Mcmanus PharmD h , Sheau-Chiann Chen PhD g , …
MD c , Marwan M. Azar MD b , Dayna Mcmanus PharmD h , Sheau-Chiann Chen PhD g , …
Antibodies to PfSEA-1 block parasite egress from RBCs and protect against malaria infection
…, CG DiPetrillo, S Pond-Tor, HW Wu, G Jolly, L Pischel… - Science, 2014 - science.org
Novel vaccines are urgently needed to reduce the burden of severe malaria. Using a
differential whole-proteome screening method, we identified Plasmodium falciparum schizont …
differential whole-proteome screening method, we identified Plasmodium falciparum schizont …
[HTML][HTML] High-resolution epitope mapping and characterization of SARS-CoV-2 antibodies in large cohorts of subjects with COVID-19
…, B Martinez, M Catherine Muenker, L Pischel… - Communications …, 2021 - nature.com
As Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to spread,
characterization of its antibody epitopes, emerging strains, related coronaviruses, and even …
characterization of its antibody epitopes, emerging strains, related coronaviruses, and even …
Crossover control study of the effect of personal care products containing triclosan on the microbiome
Commonly prescribed antibiotics are known to alter human microbiota. We hypothesized
that triclosan and triclocarban, components of many household and personal care products (…
that triclosan and triclocarban, components of many household and personal care products (…
Serum neutralizing antibody titers 12 months after coronavirus disease 2019 messenger RNA vaccination: correlation to clinical variables in an adult, US population
Background We studied whether comorbid conditions affect strength and duration of
immune responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
immune responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
[HTML][HTML] A review of COVID-19 transmission dynamics and clinical outcomes on cruise ships worldwide, January to October 2020
Background Cruise ships provide an ideal setting for transmission of SARS-CoV-2, given the
socially dense exposure environment. Aim To provide a comprehensive review of COVID-…
socially dense exposure environment. Aim To provide a comprehensive review of COVID-…
Tocilizumab treatment for cytokine release syndrome in hospitalized patients with coronavirus disease 2019.
Background: Tocilizumab, an IL-6 receptor antagonist, can be used to treat cytokine release
syndrome (CRS), with observed improvements in a coronavirus disease 2019 (COVID-19) …
syndrome (CRS), with observed improvements in a coronavirus disease 2019 (COVID-19) …
Real world effectiveness of COVID-19 mRNA vaccines against hospitalizations and deaths in the United States
Background Covid-19 has caused significant global mortality. Multiple vaccines have
demonstrated efficacy in clinical trials though real-world effectiveness of vaccines against Covid-19 …
demonstrated efficacy in clinical trials though real-world effectiveness of vaccines against Covid-19 …
Adenovirus-based vaccines and thrombosis in pregnancy: a systematic review and meta-analysis
Background Rare cases of thrombosis and thrombocytopenia (thrombosis with thrombocytopenia
syndrome [TTS]) have been associated with 2 coronavirus disease 2019 adenovirus …
syndrome [TTS]) have been associated with 2 coronavirus disease 2019 adenovirus …
Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia
Major options for second‐line therapy in adults with chronic immune thrombocytopenia (ITP)
include splenectomy, rituximab, and thrombopoietin receptor agonists (TRAs). The …
include splenectomy, rituximab, and thrombopoietin receptor agonists (TRAs). The …
